← Research library

Effect of Cortexin on neuroplasticity in multiple sclerosis

Observational study · 2009

What was studied
20 adults with relapsing-remitting MS in stable remission; 7 men and 13 women, ages 27–43
Main finding
Depression and quality-of-life scores improved in an open MS cohort; the disability score did not change significantly.

Beck depression score · 17.6 ± 1.3 → 12.9 ± 1.4 points · Within-person change; 12 participants had depressive symptoms at baseline · After the treatment program · p<0.05 versus baseline

Reported findings and study design

Depression and quality-of-life scores improved in an open MS cohort; the disability score did not change significantly.

20 adults with relapsing-remitting MS in stable remission; two ten-day courses of 10 mg intramuscular Cortexin with a two-week interval; no control group.

Population or model 20 adults with relapsing-remitting MS in stable remission; 7 men and 13 women, ages 27–43

Results · Publisher full-text results narrative and available tables checked on 1 November 2026
MeasureResultComparison, timing and statistics
Beck depression score17.6 ± 1.3 → 12.9 ± 1.4 pointsWithin-person change; 12 participants had depressive symptoms at baseline · After the treatment program · p<0.05 versus baseline
EQ-5D health score0.41 ± 0.07 → 0.73 ± 0.03Within-person change; higher score indicates better reported health · After treatment · p<0.05 versus baseline
EDSS disabilityNo significant changeParticipants entered in remission with EDSS below 3
Adverse eventsNone observed in 20 participantsSmall, short open study; not a long-term safety estimate

These results concern symptoms and quality of life in an uncontrolled cohort. Stable EDSS during a short remission-period study does not demonstrate remyelination or prevention of disease progression.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • Open prospective study without a control group, randomization or blinding.
  • Participants were already in remission; stable EDSS does not demonstrate prevention of progression.
  • No adverse events were observed in this small sample; safety and disease modification are not established.

Source details

Publisher article and Russian PDF

Publisher full-text results narrative and available tables checked on 1 November 2026

Sources checked

Citation

Uncontrolled human reportFull text available

S. V. Kotov, T. I. Yakushina, V. Yu. Lizhdvoy. Effect of Cortexin on neuroplasticity in multiple sclerosis Effective Pharmacotherapy. Neurology and Psychiatry. 2009;(3):14–16

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards